Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3712996 | 0.85 | SIGMAR1 (0.73) | ALDH1A1KDM4ELMNAPKMSMN1; SMN2 | |
| SCHEMBL3143577 | 0.84 | NPSR1 (0.70) | ALDH1A1KDM4ELMNAPKMSMN1; SMN2 | |
| SCHEMBL3326595 | 0.84 | SIGMAR1 (0.55) | ALDH1A1SIGMAR1TSHRNPSR1MAPK1 | |
| SCHEMBL12640172 | 0.81 | ALDH1A1 (0.68) | ALDH1A1KDM4ELMNAPKMSMN1; SMN2 | |
| SCHEMBL18972371 | 0.80 | ALDH1A1 (0.56) | ALDH1A1KDM4ELMNAPKMSMN1; SMN2 | |
| SCHEMBL16359721 | 0.79 | USP2 (0.69) | ALDH1A1KDM4ELMNAPKMSMN1; SMN2 | |
| SCHEMBL19068937 | 0.79 | ALDH1A1 (0.56) | ALDH1A1KDM4ELMNAPKMSMN1; SMN2 | |
| SCHEMBL27542635 | 0.78 | ALDH1A1 (0.50) | ALDH1A1KDM4ELMNAPKMSMN1; SMN2 | |
| SCHEMBL301798 | 0.78 | ALDH1A1 (0.68) | ALDH1A1KDM4ELMNAPKMSMN1; SMN2 | |
| SCHEMBL10816772 | 0.78 | CA12 (0.73) | ALDH1A1KDM4ELMNAPKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270877-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270877-A1 | IRE-1alpha INHIBITORS | XBP1, ERN1, ATF4 | ALDH1A1 2304/4885KDM4E 2748/4885LMNA 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.